Filing Flows › Celularity (CELU) › Q2 2026 › vs Q2 2025
Celularity (CELU) Q2 2026 vs Q2 2025 (year over year)
Celularity's revenue fell $304K (-5%) from $5.7M in Q2 2025 to $5.4M in Q2 2026. The biggest changes: Product +$1.7M (+71%); License Royalty and Other −$1.4M (-65%); Service −$623K (-49%).
Celularity, Q2 2026: revenue $5.4M (-5% year over year), operating margin -78.0%, net earnings $706K, operating cash flow −$1.1M. The chart draws each line against Q2 2025, the increases inside each band.
Every line
| Line | Q2 2026 | Q2 2025 | Change | % |
|---|---|---|---|---|
| Product | $4.1M | $2.4M | $1.7M | +71% |
| License Royalty and Other | $719K | $2.1M | −$1.4M | -65% |
| Service | $652K | $1.3M | −$623K | -49% |
| Revenue | $5.4M | $5.7M | −$304K | -5% |
| Other income, net | $4.9M | −$8.7M | $13.6M | — |
| Costs & expenses | $10.4M | $30.3M | −$19.9M | -66% |
| Operating costs | $9.7M | $21.6M | −$11.9M | -55% |
| Net earnings | $706K | −$24.5M | $25.2M | — |
| Cost of revenue | $2.3M | $5.2M | −$2.9M | -55% |
| Research & development | $2.0M | $3.4M | −$1.3M | -39% |
| SG&A | $4.9M | $12.6M | −$7.7M | -61% |
| Other operating costs | $354K | $372K | −$18K | -5% |
| Operating cash sources | $4.2M | −$21.6M | $25.8M | — |
| Depreciation & amortization | $1.5M | $1.8M | −$295K | -16% |
| Share-based compensation | $844K | $108K | $736K | +681% |
| Cash used in operations | $1.1M | $999K | $109K | +11% |
| Working capital & other | $4.2M | −$21.6M | $25.8M | — |
Questions
How much did Celularity's revenue grow year over year in Q2 2026?
Celularity's revenue fell $304K (-5%) from $5.7M in Q2 2025 to $5.4M in Q2 2026.
What drove Celularity's revenue change in Q2 2026?
Product +$1.7M (+71%); License Royalty and Other −$1.4M (-65%); Service −$623K (-49%).